<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="covidseq/PMC7094556/results/search/funders/results.xml">
  <result pre="; font-style : italic;} Mayo Clin Proc Mayo Clin. Proc" exact="Mayo Clinic" post="Proceedings 0025-6196 1942-5546 Mayo Foundation for Medical Education and"/>
  <result pre="Clin Proc Mayo Clin. Proc Mayo Clinic Proceedings 0025-6196 1942-5546" exact="Mayo Foundation for Medical Education and Research" post="pmcid: 7094556 S0025-6196(19)30483-5 doi: 10.1016/j.mayocp.2019.05.016 : Article Zika Vaccine"/>
  <result pre="[], ∗ Correspondence: Address to Gregory A. Poland, MD, Director," exact="Mayo Clinic" post="Vaccine Research Group, Mayo Clinic, 200 First St SW,"/>
  <result pre="Gregory A. Poland, MD, Director, Mayo Clinic Vaccine Research Group," exact="Mayo Clinic," post="200 First St SW, Rochester, MN 55905. poland.gregory@mayo.edu pmc-release:"/>
  <result pre="2019-12-12 ppub: 2019-12 epub: 2019-12-12 94 12 2572 2586 (C)" exact="Mayo Foundation for Medical Education and Research," post="2019 Since January 2020 Elsevier has created a COVID-19"/>
  <result pre="IRF, IFN response factor mRNA, messenger RNA prM, premembrane/membrane WHO," exact="World Health Organization" post="ZIKV, Zika virus While discovered in 1947, Zika virus"/>
  <result pre="briefly into the United States. On February 1, 2016, the" exact="World Health Organization" post="(WHO) declared a Public Health Emergency of International Concern"/>
  <result pre="dark green (current as of March 2018). Data from the" exact="Centers for Disease Control and Prevention." post="16 B, Countries suitable for Aedes aegypti and Aedes"/>
  <result pre="= antibody; IM = intramuscular; SC = subcutaneous; WHO =" exact="World Health Organization;" post="ZIKV = Zika virus. Data from the World Health"/>
  <result pre="World Health Organization; ZIKV = Zika virus. Data from the" exact="World Health Organization." post="47 Zika Immunology Both type I and type III"/>
  <result pre="mRNA-based vaccine Geovax Labs, Inc Early-stage research Live MVA recombinant" exact="GlaxoSmithKline" post="plc Early-stage research Self-amplifying mRNA platform Whole, inactivated virus"/>
  <result pre="adenovirus recombinant Protein Sciences Corporation Early-stage research Recombinant envelope protein" exact="Sanofi" post="Early-stage research YF17D chimera Sementis Early-stage research Live poxvirus"/>
  <result pre="Live measles recombinant Valneva SE Early-stage research Purified inactivated virus" exact="Mayo Clinic" post="Vaccine Research Group Early-stage research Naturally processed and HLA-presented"/>
  <result pre="nanoparticle–delivered mRNA Emergent BioSolutions Inc Early-stage research Inactivated, whole virus" exact="Institut Pasteur" post="of Shanghai Early-stage research Recombinant subunit VLP Takeda Pharmaceutical"/>
  <result pre="virus Institut Pasteur of Shanghai Early-stage research Recombinant subunit VLP" exact="Takeda Pharmaceutical Company" post="Limited Early-stage research Alum adjuvanted, inactivated whole virus Edward"/>
  <result pre="proteins Vaxart, Inc Early-stage research Recombinant oral vaccine CDC =" exact="Centers for Disease Control and Prevention;" post="DENV= dengue virus; mRNA = messenger RNA; MVA ="/>
  <result pre="messenger RNA; MVA = modified vaccinia virus ankara; NIH =" exact="National Institutes of Health;" post="R&amp;amp;D = research and development; VLP = virus-like particles;"/>
  <result pre="of the Aedes vectors. Governmental agencies such as the US" exact="Food and Drug Administration" post="and the European Medicines Agency are exploring pathways for"/>
  <result pre="of other preclinical-stage vaccine candidates are currently being developed. The" exact="Mayo Clinic" post="Vaccine Research Group is using an established mass spectrometry"/>
  <result pre="published. 48 This problem may require the use of the" exact="Food and Drug Administration" post="animal rule, human challenge studies, passive transfer animal studies,"/>
  <result pre="J Med 373 4 2015 297 300 26200974 3 collab:" exact="Centers for Disease Control and Prevention" post="Zika virus: statistics and maps https://www.cdc.gov/zika/reporting/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fzika%2Freporting%2Fcase-counts.html 4 Leder K."/>
  <result pre="Brazil Lancet 387 10016 2016 335 336 26777915 16 collab:" exact="Centers for Disease Control and Prevention" post="Zika travel information https://wwwnc.cdc.gov/travel/page/zika-travel-information Updated May 15, 2019 17"/>
  <result pre="Int J Infect Dis 67 2018 25 35 29196275 18" exact="World Health Organization" post="Zika virus https://www.who.int/news-room/fact-sheets/detail/zika-virus Published July 20, 2018 19 Johansson"/>
  <result pre="case-control study Lancet 387 10027 2016 1531 1539 26948433 26" exact="World Health Organization" post="ZIka situation report https://www.who.int/emergencies/zika-virus/situation-report/who-zika-situation-report-12-02-2016.pdf?ua=12016 Published February 12, 2016 27"/>
  <result pre="Organization ZIka situation report https://www.who.int/emergencies/zika-virus/situation-report/who-zika-situation-report-12-02-2016.pdf?ua=12016 Published February 12, 2016 27" exact="World Health Organization" post="Guillain-Barré syndrome – Brazil https://www.who.int/csr/don/8-february-2016-gbs-brazil/en/ Published February 8, 2016"/>
  <result pre="challenge model Sci Rep 7 1 2017 14769 29116169 47" exact="World Health Organization" post="Zika virus vaccine product development https://www.who.int/immunization/research/development/zika/en/ 48 Vannice K.S."/>
  <result pre="Evaluation Committee for novel investigational vaccine trials being conducted by" exact="Merck" post="Research Laboratories and is a consultant on vaccine development"/>
  <result pre="Research Laboratories and is a consultant on vaccine development to" exact="Merck" post="&amp;amp; Co. Inc, Avianax LLC, Adjuvance, Valneva SE, Medicago"/>
  <result pre="&amp;amp; Co. Inc, Avianax LLC, Adjuvance, Valneva SE, Medicago Inc," exact="Sanofi" post="Pasteur Limited, GlaxoSmithKline plc, and Emergent BioSolutions Inc. Drs"/>
  <result pre="Avianax LLC, Adjuvance, Valneva SE, Medicago Inc, Sanofi Pasteur Limited," exact="GlaxoSmithKline" post="plc, and Emergent BioSolutions Inc. Drs Poland and Ovsyannikova"/>
  <result pre="related to vaccinia peptide vaccines and has received funding from" exact="Merck" post="Research Laboratories to study waning immunity to mumps vaccine."/>
  <result pre="to mumps vaccine. These activities have been reviewed by the" exact="Mayo Clinic" post="Conflict of Interest Review Board and are conducted in"/>
  <result pre="of Interest Review Board and are conducted in compliance with" exact="Mayo Clinic" post="Conflict of Interest policies. This research has been reviewed"/>
  <result pre="of Interest policies. This research has been reviewed by the" exact="Mayo Clinic" post="Conflict of Interest Review Board and was conducted in"/>
  <result pre="of Interest Review Board and was conducted in compliance with" exact="Mayo Clinic" post="Conflict of Interest policies."/>
 </snippets>
</snippetsTree>
